RxDoctor Payments Data

Steven Mitchell

Neurology · Kalamazoo, MINPI 1710411509

Payments from drug & device makers

$20,506in general payments, 2019–2025

Across 81 payments — averaging $253.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$16K
  • Abbott$1K
  • Boston Scientific$972
  • Teva Pharmaceuticals USA, Inc.$347
  • Novartis$230
  • Biogen$228
  • plus $2K from 15 others

What the payments were for

  • Grants$15,00073%
  • Travel & lodging$2,45512%
  • Food & beverage$2,83914%
  • Education$2111%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,506 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$56,362
Medicare patients
278
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate26$206,575
AustedoDeutetrabenazine12$184,553
RytaryCarbidopa/Levodopa34$83,312
NuplazidPimavanserin Tartrate15$74,956
GocovriAmantadine Hcl14$47,258
Carbidopa-LevodopaCarbidopa/Levodopa739$34,742
OngentysOpicapone13$20,854
Carbidopa-Levodopa ErCarbidopa/Levodopa171$12,973
Carbidopa21$8,428
Primidone221$8,055
Propranolol Hcl ErPropranolol Hcl138$5,156
Ropinirole ErRopinirole Hcl44$4,382
AmantadineAmantadine Hcl34$2,421
Eletriptan HbrEletriptan Hydrobromide14$2,149
Ropinirole Hcl57$1,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$120$227,42839 claims
Teva Pharmaceuticals USA, Inc.Austedo$347$184,55312 claims
Amneal Pharmaceuticals LLCRytary$125$83,31234 claims
Acadia Pharmaceuticals IncNuplazid$154$74,95615 claims
MDD US Operations, LLCGocovri$101$47,25814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →